October 03, 2019
New 48-Week Data Presented at IDWeek Show Trogarzo® Remains Safe and Effective
Montreal, Canada – October 3, 2019 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new 48-week data from the TMB-311 extension study confirm that Trogarzo® provides durable viral suppression and a safety profile consistent with the 24-week pivotal Phase III study. Study results were presented today at IDWeekTM in Washington, D.C.
Results come from the expanded access protocol of TMB-311. A total of 38 patients were enrolled in Cohort 2. Patients had a viral load >1,000 copies/mL, resistance to at least 1 antiretroviral from three different classes and full viral sensitivity to at least 1 antiretroviral.